Acknowledgements The work was partially supported by the Research Council of Norway through its Centres of Excellence scheme, project number 332727, and grant 274993 (J.T.A., J.N., and S.B.), grant 287927 (J.T.A., K.H.A., and F.R.J.), and grant 285136 (J.T.A.)
O'Hara, A
Allergic responses are possible with any injected peptide and are hard to predict
Key Takeaways: Read also: AI Boom Powers Memory Chip Rally as China Gains Pfizer keeps expanding its GLP-1 portfolio in China through its second licensing deal in just a few months Ecnoglutide is a once-weekly injection already approved in China, with a weight management application currently under review Competition in the GLP-1 space is heating up fast, with heavyweights like Novo Nordisk and Eli Lilly already leading the pack Ecnoglutide belongs to a class of drugs known as GLP-1 receptor agonists, the same category as Novo Nordisk's Ozempic and Eli Lilly's Mounjaro
Widespread use of GLP-1 RAs was projected to prevent 6211 MIs, 7467 strokes, 18,236 HF hospitalisations and 8257 deaths, but increase the number of ESKD events by 314
